A Look At Telix Pharmaceuticals (ASX:TLX) Valuation After Recent FDA And Pipeline Milestones

Telix Pharmaceuticals (ASX:TLX) is back in focus after the FDA accepted its resubmitted New Drug Application for brain imaging agent Pixclara and the company reaffirmed its FY2026 revenue guidance alongside several late stage pipeline updates. See our latest analysis for Telix Pharmaceuticals. At A$14.52, Telix’s stock has given investors a 59.91% 90 day share price return and a 27.82% year to date share price return, yet the 1 year total shareholder return is down 43.19%, so near term momentum contrasts with weaker recent history. If Telix’s regulatory news has you thinking more broadly about radiopharmaceutical and healthcare imaging opportunities, it could be worth scanning other specialised healthcare AI plays via 9 healthcare AI stocks With Telix shares rallying in recent months but still trading at a large discount to analyst price targets, the key question now is whether the current price undervalues its radiopharmaceutical pipeline or already reflects future growth expectations. Most Popular Narrative: 19.3% Undervalued According to the most followed narrative, Telix’s fair value of A$18.00 sits well above the current A$14.52 share price. This frames the recent FDA news within a wider thesis about its imaging platform, manufacturing buildout and future therapeutics potential. On top of that, they''re vertically integrating manufacturing and distribution through a handful of acquisitions (RLS, ARTMS, Iso Therapeutics). Less reliance on third parties may mean better margins and more supply reliability over time. *In theory*. Read the complete narrative. Want to see what sits behind that confidence in Telix’s revenue mix and future earnings power? The narrative leans heavily on pipeline progress, maturing imaging volumes and a forward profit multiple more often associated with fast growing healthcare platforms. Result: Fair Value of A$18.00 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, this hinges on clinical trials and regulatory processes progressing as hoped, with setbacks or pricing pressure in PSMA imaging potentially forcing a rethink of that upside case. Find out about the key risks to this Telix Pharmaceuticals narrative. Next Steps Given the mix of optimism and uncertainty in the story so far, it makes sense to move quickly, review the data and form your own view of the stock. You can then weigh those potential upsides in detail through 3 key rewards. Looking for more investment ideas? If you stop with just one stock, you miss the chance to spot other opportunities that might fit your goals even better, so put the Simply Wall St Screener to work. Target potential upside by scanning for quality opportunities that still trade below their implied worth using the 10 high quality undervalued stocks. Strengthen your core holdings by focusing on companies with robust finances through the solid balance sheet and fundamentals stocks screener (18 results). Get ahead of the crowd by searching for quality stocks that are not widely followed yet via the screener containing 13 high quality undiscovered gems. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Telix Pharmaceuticals might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free Analysis